Moira Garraus

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Cerebrospinal Fluid

Hodgkin Lymphoma

Stem Cell Transplantation

Patient Reported Outcomes

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Maite Gorostegui, Juan Pablo Muñoz, Sara Perez-Jaume, Margarida Simao-Rafael, Cristina Larrosa, Moira Garraus, Noelia Salvador, Cinzia Lavarino, Lucas Krauel, Salvador Mañe, Alicia Castañeda, Jaume Mora
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy. Cancers 16 (9) (2024)
Maite Gorostegui, Juan Pablo Muñoz, Sara Perez-Jaume, Margarida Simao-Rafael, Cristina Larrosa, Moira Garraus, Noelia Salvador, Cinzia Lavarino, Lucas Krauel, Salvador Mañe, Alicia Castañeda, Jaume Mora
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy. Cancers 16 (9) (2024)
Jaume Mora, Alicia Castañeda, Maite Gorostegui, Amalia Varo, Sara Perez-Jaume, Margarida Simao, Juan Pablo Muñoz Pérez, Moira Garraus, Cristina Larrosa, Noelia Salvador, Cinzia Lavarino, Lucas Krauel, Salvador Mañe
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report. Cancers 15 (9) (2023)
Jaume Mora, Alicia Castañeda, Maite Gorostegui, Amalia Varo, Sara Perez-Jaume, Margarida Simao, Juan Pablo Muñoz Pérez, Moira Garraus, Cristina Larrosa, Noelia Salvador, Cinzia Lavarino, Lucas Krauel, Salvador Mañe
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report. Cancers 15 (9) (2023)
Jaume Mora, Alicia Castañeda, Maria Cecilia Colombo, Maite Gorostegui, Fernando Gómez Muñoz, Salvador Mañe, Vicente Santa-Maria, Moira Garraus, Napoleon Macias, Sara Perez-Jaume, Oscar Muñoz, Juan Pablo Muñoz Pérez, Ignasi Barber, Mariona Suñol
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers 13 (6) (2021)